OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

Sandoz Group AG SANDOZ GROUP ORD .../  CH1243598427  /

LSE International Off-book
2024-10-04  6:18:28 PM Chg. +0.36 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
35.27CHF +1.03% 80,416
Turnover: 2.81 mill.		 -Bid Size: - -Ask Size: - 16.17 bill.CHF - -
GlobeNewswire 08-12 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire 08-08 Sandoz reports second-quarter sales and half-year 2024 results
GlobeNewswire 07-25 Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory dise...
GlobeNewswire 07-01 FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
GlobeNewswire 05-22 Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire 05-07 Sandoz reports first quarter 2024 sales
GlobeNewswire 04-30 Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire 04-30 Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire 04-22 Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire 03-21 Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire 03-13 Sandoz reports fourth quarter 2023 sales and full-year 2023 results
GlobeNewswire 03-05 Sandoz receives FDA approval for first and only denosumab biosimilars
GlobeNewswire 03-05 Sandoz announces nominations to the Board of Directors and leadership change
GlobeNewswire 03-04 Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire 02-29 Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire 02-01 Sandoz announces changes in the Board of Directors
GlobeNewswire 01-31 Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire 01-22 Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire 2023-11-21 Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...
GlobeNewswire 2023-11-10 Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center ...
GlobeNewswire 2023-11-08 Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds
GlobeNewswire 2023-10-26 Sandoz successfully issues CHF 750 million in inaugural bonds
GlobeNewswire 2023-10-24 Sandoz reports year-to-date sales for the first nine months of 2023
TeleTrader 2023-10-04 Sandoz seals spin-off from Novartis, starts trading
GlobeNewswire 2023-10-04 Sandoz enters new era as standalone global leader and European champion in generic and biosimilar me...